|
1）Elhassan EA, Schrier RW. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens. 2011; 20: 161-8
|
|
|
|
2）Schrier RW. The science behind hyponatremia and its clinical manifestations. Pharmacotherapy. 2011; 31: 9S-17S
|
|
|
|
|
|
3）Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008; 101: 583-8
|
|
|
|
|
|
4）Tolouian R, Alhamad T, Farazmand M, et al. The correlation of hip fracture and hyponatremia in the elderly. J Nephrol. 2012; 25: 789-93
|
|
|
|
|
|
5）Hoorn EJ, Liamis G, Zietse R, et al. Hyponatremia and bone: an emerging relationship. Nat Rev Endocrinol. 2011; 8: 33-9
|
|
|
|
|
|
6）Kinsella S, Moran S, Sullivan MO, et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010; 5: 275-80
|
|
|
|
|
|
7）Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-112
|
|
|
|
|
|
8）Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010; 21: 705-12
|
|
|
|
|
|
9）Reynolds RM, Padfield PL, Seckl JR. Disorders of sodium balance. BMJ. 2006; 332: 702-5
|
|
|
|
|
|
10）Tanemoto M. Regulatory mechanism of “K+recycling” for Na +reabsorption in renal tubules. Clin Exp Nephrol. 2007; 11: 1-6
|
|
|
|
|
11）Maesaka JK, Imbriano LJ, Ali NM, et al. Is it cerebral or renal salt wasting? Kidney Int. 2009; 76: 934-8
|
|
|
|
|
|
12）Ward DT, Hammond TG, Harris HW. Modulation of vasopressin-elicited water transport by trafficking of aquaporin2-containing vesicles. Annu Rev Physiol. 1999; 61: 683-97
|
|
|
|
|
|
13）Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol. 2008; 3: 1175-84
|
|
|
|
|
|
14）Gankam Kengne F, Soupart A, Pochet R, et al. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int. 2009; 76: 614-21
|
|
|
|
|
|
15）Cerda-Esteve M, Cuadrado-Godia E, Chillaron JJ, et al. Cerebral salt wasting syndrome: review. Eur J Intern Med. 2008; 19: 249-54
|
|
|
|
|
|
16）Maesaka JK, Wolf-Klein G, Piccione JM, et al. Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J Am Geriatr Soc. 1993; 41: 501-6
|
|
|
|
|
|
17）Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003; 41: 211-4
|
|
|
|
|
|
18）Egom EE, Chirico D, Clark AL. A review of thiazide-induced hyponatraemia. Clin Med. 2011; 11: 448-51
|
|
|
|
|
|
19）Hix JK, Silver S, Sterns RH. Diuretic-associated hyponatremia. Semin Nephrol. 2011; 31: 553-66
|
|
|
|
|
|
20）Leung AA, Wright A, Pazo V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011; 124: 1064-72
|
|
|
|
|
|
21）Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010; 25: 554-63
|
|
|
|
|
|
22）Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem. 2011; 286: 10864-75
|
|
|
|
|
|
23）DeWolfe A, Lopez B, Arcement LM, et al. Low serum sodium as a poor prognostic indicator for mortality in congestive heart failure patients. Clin Cardiol. 2010; 33: 22
|
|
|
|
|
|
24）Doshi SM, Shah P, Lei X, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012; 59: 222-8
|
|
|
|
|
|
25）Goldberg A, Hammerman H, Petcherski S, et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med. 2006; 166: 781-6
|
|
|
|
|
|
26）Klein L, O’Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005; 111: 2454-60
|
|
|
|
|
|
27）Kovesdy CP, Lott EH, Lu JL, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012; 125: 677-84
|
|
|
|
|
|
28）Romanovsky A, Bagshaw S, Rosner MH. Hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy. Int J Nephrol. 2011; Article ID 732746: 1-7
|
|
|
|
|
|
29）Waikar SS, Curhan GC, Brunelli SM. Mortality associated with low serum sodium concentration in maintenance hemodialysis. Am J Med. 2011; 124: 77-84
|
|
|
|
|
|
30）Decaux G, Brimioulle S, Genette F, et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med. 1980; 69: 99-106
|
|
|
|
|
|
31）Coussement J, Danguy C, Zouaoui-Boudjeltia K, et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically ill patients. Am J Nephrol. 2012; 35: 265-70
|
|
|
|
|